A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia.

Randomized controlled trial · J Psychopharmacol · 2016. Source record refreshed; an explanation has not been reviewed.

About this paper

This page identifies the publication and its source. A checked explanation of its findings is not yet available.

Reading this record

Checking bibliographic metadata does not verify a study’s conclusions or any advice previously linked to it.

CHECK THE ORIGINAL

Girgis RR, Van Snellenberg JX, Glass A et al.
J Psychopharmacol · 2016

A checked publication record confirms source details. It does not verify a health claim or assess the quality of the study. Our approach.